32qp棋牌游戏平台下载

33彩票网手机下载
22彩票手机客户端
2690手机棋牌游戏
258彩票app下载
33彩票购大厅
248彩票
235cc彩票网
259彩票app下载苹果
33彩票网合法
MNK Recent Acquisitions
Our Story
Partnering
Patient Stories
150th Anniversary

310比分网

2020|2019|2017|2016

Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement (RRT) Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated with TerlipressinOct 29, 2020
Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business OperationsOct 14, 2020
Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 RestructuringOct 12, 2020
Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)Sep 14, 2020
Mallinckrodt Announces 2020 Investigator Award to Further Advances in ECP ImmunomodulationAug 31, 2020
Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership AwardsAug 24, 2020
Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal BurnsAug 10, 2020
Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline AdvancementsAug 04, 2020
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)Jul 15, 2020
Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in AdultsJul 12, 2020
Mallinckrodt to Report Earnings Results for Second Quarter 2020Jul 09, 2020
Mallinckrodt Confirms that U.S. Food and Drug Administration (FDA) Will Convene an Advisory Committee to Review Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)Jul 07, 2020
Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare ConferenceJun 17, 2020
Mallinckrodt to Proceed with Appeal Despite Appellate Court Decision Denying Temporary Injunction in Ongoing Acthar Gel Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)Jun 15, 2020
Mallinckrodt to Present Phase 3 StrataGraft® Regenerative Skin Tissue Clinical Trial Results on Severe Burns During the Virtual American Burn Association 52nd Annual MeetingJun 15, 2020
Real-World Data of Terlipressin in Hospitalized Patients in U.K. with Hepatorenal Syndrome Type 1 (HRS-1) Published in Alimentary Pharmacology and TherapeuticsJun 11, 2020
Mallinckrodt Completes Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug AdministrationJun 09, 2020
Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)Jun 01, 2020
Mallinckrodt plc Reports Earnings for the First Quarter 2020 and Highlights Pipeline ProgressMay 05, 2020
Mallinckrodt Announces Positive Findings in INOmax® (Nitric Oxide) Gas, for Inhalation Phase 4 Observational Registry in Neonates with Pulmonary Hypertension; Ends Trial EarlyMay 04, 2020
Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19Apr 30, 2020
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of New Drug Application for Terlipressin for Treatment of Hepatorenal Syndrome Type 1 (HRS-1)Apr 22, 2020
Mallinckrodt to Report Earnings Results for First Quarter 2020Apr 16, 2020
Mallinckrodt Announces Publication of Data on Acthar® Gel (Repository Corticotropin Injection) from its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study in Rheumatoid Arthritis (RA) in Rheumatology and TherapyApr 15, 2020
Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug AdministrationApr 06, 2020
Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung ComplicationsApr 01, 2020
Mallinckrodt Pharmaceuticals Statement Regarding Product SupplyMar 20, 2020
Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)Mar 17, 2020
Mallinckrodt Confirms Court Decision in Lawsuit Against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and Provides Update Related to Global Opioid Settlement and Present Financing ActivitiesMar 16, 2020
Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory AgenciesMar 12, 2020
Mallinckrodt Provides Update on Proposed Global Opioid SettlementMar 11, 2020
Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Immunoglobulin A Nephropathy (IgAN) Published in Kidney International ReportsMar 05, 2020
Mallinckrodt Announces Publication of New Data on Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Dermatomyositis/Polymyositis Published in Open Access Rheumatology: Research and ReviewsMar 04, 2020
Mallinckrodt Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)Mar 02, 2020
Mallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020Feb 27, 2020
Mallinckrodt plc Reports Strong Fourth Quarter and 2019 ResultsFeb 25, 2020
Mallinckrodt Announces Agreement in Principle for Global Opioid Settlement and Associated Debt Refinancing ActivitiesFeb 25, 2020
Mallinckrodt to Report Earnings Results for Fourth Quarter and Fiscal 2019Feb 14, 2020
Mallinckrodt Recognized as one of the "2020 Best Places to Work for LGBTQ Equality"Jan 30, 2020
Mallinckrodt to Present at the 38th Annual J.P. Morgan Healthcare ConferenceDec 23, 2019
First Patient Enrolled in Mallinckrodt Phase 4 Trial of Acthar® Gel (Repository Corticotropin Injection) for Severe KeratitisDec 16, 2019
Mallinckrodt Announces Plans to Update Its Incentive Compensation Clawback Policy and Create Opioid ReportDec 10, 2019
Mallinckrodt Presents Data on a Novel Predictive Model to Identify Infants at Risk for Infantile Spasms (IS) at the 2019 Annual Meeting of the American Epilepsy Society (AES)Dec 07, 2019
Mallinckrodt plc Announces Final Results of Exchange TransactionsDec 05, 2019
Mallinckrodt Moves Date and Time of Its Fireside Chat at Piper Jaffray Annual Healthcare ConferenceDec 02, 2019
Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis Published in Therapeutic Advances in Respiratory DiseaseNov 26, 2019
Mallinckrodt plc Announces Early Results of Exchange TransactionsNov 19, 2019
Mallinckrodt to Present at Piper Jaffray Annual Healthcare ConferenceNov 19, 2019
Mallinckrodt Announces New Clinical Data Evaluating Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual MeetingNov 12, 2019
Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019Nov 11, 2019
Mallinckrodt to Present at Jefferies London Healthcare ConferenceNov 08, 2019
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan PopulationNov 07, 2019
Mallinckrodt plc Announces Exchange Offers and Consent SolicitationsNov 05, 2019
Mallinckrodt plc Reports Earnings and Pipeline Advancements for the Third Quarter 2019 and Raises Adjusted Diluted Earnings Per Share Guidance Range for 2019Nov 05, 2019
Mallinckrodt Completes Sale of BioVectra Inc. for up to $250 MillionNov 04, 2019
Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in AdultsOct 31, 2019
Mallinckrodt Announces Launch of 2020 Award in Support of Advancing ECP ImmunomodulationOct 22, 2019
Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care WeekOct 21, 2019
Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019Oct 21, 2019
Mallinckrodt to Report Earnings Results for Third Quarter 2019Oct 09, 2019
Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection)Oct 01, 2019
Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and SummitSep 30, 2019
Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal BurnsSep 23, 2019
Mallinckrodt to Present at Cantor Global Healthcare ConferenceSep 20, 2019
Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis RelapseSep 13, 2019
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 MillionSep 10, 2019
Mallinckrodt Announces Settlement in Principle to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and SummitSep 06, 2019
Mallinckrodt Announces Completion of Previously Disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor Sales and Marketing ActivitiesSep 03, 2019
Mallinckrodt Comments on U.S. Court of Appeals Ruling in Patent Infringement Lawsuit against Praxair, Inc.Aug 27, 2019
Mallinckrodt to Present at Morgan Stanley 17th Annual Global Healthcare ConferenceAug 21, 2019
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)Aug 15, 2019
Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in BurnsAug 13, 2019
First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)Aug 12, 2019
Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-offAug 06, 2019
Mallinckrodt to Present at Wells Fargo Securities 2019 Healthcare ConferenceAug 02, 2019
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated DiseasesJul 18, 2019
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated DiseasesJul 18, 2019
Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)Jul 16, 2019
Mallinckrodt to Report Earnings Results for Second Quarter 2019Jul 01, 2019
Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)Jun 24, 2019
All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)Jun 13, 2019
Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare ConferenceJun 11, 2019
Mallinckrodt Announces Agreement In Principle With U.S. Department Of Justice On Legacy Questcor Sales And Marketing Activities; Responds To Government Civil Litigation Involving Legacy Questcor Charitable Foundation ActivitiesJun 05, 2019
Mallinckrodt Pharmaceuticals Data Presented at Annual Scientific ConferenceJun 03, 2019
Mallinckrodt to Present at Raymond James Life Sciences and Medtech ConferenceMay 31, 2019
Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)May 29, 2019
Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to ShareholdersMay 28, 2019
Mallinckrodt Announces Election of Carlos V. Paya, M.D., Ph.D. to its Board of DirectorsMay 21, 2019
Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar® GelMay 21, 2019
Mallinckrodt Responds to Anticipated Questions Related to its Suit Against the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services (CMS, the Agency)May 21, 2019
Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM TrialMay 14, 2019
Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous PolyposisMay 07, 2019
Mallinckrodt plc Reports Strong Growth in First Quarter 2019 Results, Raises Guidance for 2019, and Continues to Make Significant Advancements in Pipeline and Data GenerationMay 07, 2019
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax® (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in NeonatesMay 06, 2019
Mallinckrodt to Present Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis at Annual European Congress of Rheumatology (EULAR 2019)May 02, 2019
Mallinckrodt States its Position on Legacy Acthar® Gel Legal MatterApr 30, 2019
Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis.Apr 24, 2019
Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage PopulationApr 23, 2019
Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung TransplantsApr 18, 2019
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)Apr 15, 2019
Mallinckrodt Continues to Refute Inaccuracies Surrounding its Financial Liabilities Oct 12, 2017
Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017Oct 10, 2017
Mallinckrodt Statement on October 7, 2017, CHEST® Journal ArticleOct 09, 2017
Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic SarcoidosisOct 09, 2017
Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor BriefingOct 04, 2017
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development ProductOct 02, 2017
Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe JaundiceSep 25, 2017
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United StatesSep 22, 2017
Mallinckrodt Announces Election Of David Norton To Its Board Of DirectorsSep 20, 2017
Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other MattersSep 12, 2017
Mallinckrodt Statement on Praxair Patent Infringement RulingSep 05, 2017
Mallinckrodt Statement on Missouri Attorney General InvestigationAug 30, 2017
Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare ConferenceAug 15, 2017
Mallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017Aug 08, 2017
Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid ProductsAug 07, 2017
Mallinckrodt To Present At Wells Fargo Securities 2017 Healthcare ConferenceAug 07, 2017
Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe JaundiceAug 04, 2017
Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid ProductsAug 02, 2017
Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In NeonatesAug 01, 2017
Summary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injection) Published in Advances in TherapyJul 31, 2017
Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring ActivitiesJul 27, 2017
Mallinckrodt Posts Data From Legacy H.P. Acthar® Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.govJul 25, 2017
U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced TherapyJul 18, 2017
Mallinckrodt Commends Governor On Ordering Prescription Drug Monitoring Program In MissouriJul 17, 2017
Mallinckrodt Confirms License Transfer of Synacthen® Depot; Continues Development Efforts for MNK-1411 in Treatment of DMDJul 16, 2017
Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of ScheduleJul 13, 2017
FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular DystrophyJul 12, 2017
Mallinckrodt Finalizes Previously Announced Agreement with DEA and USAOsJul 11, 2017
Mallinckrodt Announces Specialty Brands Investor BriefingJul 05, 2017
Mallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017Jun 29, 2017
MNK H.P. Acthar Gel DN Trial Results AlertJun 26, 2017
Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and OpinionJun 23, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) UpdateJun 22, 2017
Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within HospitalsJun 21, 2017
Mallinckrodt Reinforces Facts in Response to Business Insider “Editorial” Jun 19, 2017
Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS)Jun 14, 2017
MNK Response to Senator McCaskill LetterJun 08, 2017
Mallinckrodt Enrolls First Patient in Phase 3 Trial of StrataGraft® Regenerative Skin TissueJun 07, 2017
Mallinckrodt Updates Facts Refuting Short-Seller ClaimsJun 06, 2017
Mallinckrodt Statement on Sen. Mccaskill Inquiry Related to Ofirmev® (Acetaminophen) InjectionMay 26, 2017
Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis RelapseMay 25, 2017
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis RelapseMay 23, 2017
Mallinckrodt Presents Facts to Refute Short-Seller ClaimsMay 19, 2017
Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal CareMay 19, 2017
Mallinckrodt Opens New Global Centre for Medical Device R&DMay 15, 2017
Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare ConferenceMay 12, 2017
Mallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017May 08, 2017
First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin TissueMay 04, 2017
Mallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis TherapyMay 03, 2017
Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual MeetingApr 28, 2017
Mallinckrodt To Present At UBS Global Healthcare ConferenceApr 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Apr 20, 2017
Mallinckrodt To Present At Deutsche Bank 42nd Annual Healthcare ConferenceApr 05, 2017
Mallinckrodt Statement on DEA and USAOs Agreement in PrincipleApr 03, 2017
Mallinckrodt plc To Report Earnings Results For First Quarter Of Fiscal 2017Mar 24, 2017
Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionMar 20, 2017
Mallinckrodt plc Board Expands Company's Share Repurchase Plan by $1.0 Billion; Company Announces Results of 2017 Annual General MeetingMar 01, 2017
Mallinckrodt To Present At Barclays Global Healthcare ConferenceFeb 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Feb 22, 2017
Updated Mallinckrodt Statement on Extended-Release Methylphenidate TabletsFeb 21, 2017
Mallinckrodt plc Reports Transition Period Results and Announces 2017 GuidanceFeb 07, 2017
Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionJan 30, 2017
Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionJan 27, 2017
Mallinckrodt To Present At Leerink Partners 6th Annual Global Healthcare ConferenceJan 26, 2017
Mallinckrodt And Federal Trade Commission Resolve Questcor MatterJan 18, 2017
Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC InvestigationJan 18, 2017
Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of MallinckrodtJan 04, 2017
Mallinckrodt plc To Report Earnings Results For Transition Period Of Oct. 1, 2016, To Dec. 30, 2016, On Feb. 7, 2017Dec 29, 2016
Mallinckrodt To Present At J.P. Morgan 35th Annual Healthcare ConferenceDec 15, 2016
Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 28th Annual National Forum of the Institute for Healthcare ImprovementDec 07, 2016
Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality IndexDec 05, 2016
Mallinckrodt To Present At BMO Capital Markets 2016 Prescriptions For Success Healthcare ConferenceNov 30, 2016
Mallinckrodt plc Reports Fiscal 2016 Fourth Quarter and Full-Year ResultsNov 29, 2016
Mallinckrodt Updated Statement on Extended-Release Methylphenidate TabletsNov 23, 2016
Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar® Gel in Treatment of Amyotropic Lateral Sclerosis (ALS)Nov 21, 2016
Clinical Pharmacokinetic and Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 15th Annual Pain Medicine Meeting of ASRANov 18, 2016
Study Addresses Possible Impact of H.P. Acthar® Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/PolymyositisNov 17, 2016
Mallinckrodt Statement on Extended-Release Methylphenidate TabletsNov 16, 2016
Clinical Data Analysis on Terlipressin Presented at The Liver Meeting®Nov 16, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for LupusNov 14, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rheumatoid ArthritisNov 14, 2016
Mallinckrodt Announces U.S. FDA Approval of OFIRMEV® IV Bag PresentationNov 08, 2016
Mallinckrodt Statement on U.S. Department of Justice Generics Industry InvestigationNov 07, 2016
Mallinckrodt To Present At 28th Annual Piper Jaffray Healthcare ConferenceNov 02, 2016
Mallinckrodt Builds UK Presence with New Global Corporate Headquarters in Staines-upon-ThamesOct 28, 2016
Mallinckrodt to present at Jefferies 2016 London Healthcare ConferenceOct 26, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in West VirginiaOct 25, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in KentuckyOct 20, 2016
Mallinckrodt plc To Report Fourth Quarter And Full-Year Fiscal 2016 Results Nov. 29, 2016Oct 18, 2016
Children's National Health System Granted $3 Million in Research Funding by Mallinckrodt PharmaceuticalsOct 13, 2016
Validity of Mallinckrodt's INOMAX® Patent Claims UpheldSep 23, 2016
Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 millionSep 19, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsSep 17, 2016
Health Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in TherapySep 01, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsAug 31, 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND ApplicationAug 25, 2016
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionAug 24, 2016
Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home AffairsAug 23, 2016
Mallinckrodt To Present At Morgan Stanley Global Healthcare ConferenceAug 22, 2016
Mallinckrodt To Present At Wells Fargo Securities Healthcare ConferenceAug 19, 2016
Mallinckrodt Continues to Refute Inaccuracies Surrounding its Financial Liabilities Oct 12, 2017
Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017Oct 10, 2017
Mallinckrodt Statement on October 7, 2017, CHEST® Journal ArticleOct 09, 2017
Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic SarcoidosisOct 09, 2017
Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor BriefingOct 04, 2017
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development ProductOct 02, 2017
Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe JaundiceSep 25, 2017
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United StatesSep 22, 2017
Mallinckrodt Announces Election Of David Norton To Its Board Of DirectorsSep 20, 2017
Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other MattersSep 12, 2017
Mallinckrodt Statement on Praxair Patent Infringement RulingSep 05, 2017
Mallinckrodt Statement on Missouri Attorney General InvestigationAug 30, 2017
Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare ConferenceAug 15, 2017
Mallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017Aug 08, 2017
Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid ProductsAug 07, 2017
Mallinckrodt To Present At Wells Fargo Securities 2017 Healthcare ConferenceAug 07, 2017
Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe JaundiceAug 04, 2017
Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid ProductsAug 02, 2017
Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In NeonatesAug 01, 2017
Summary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injection) Published in Advances in TherapyJul 31, 2017
Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring ActivitiesJul 27, 2017
Mallinckrodt Posts Data From Legacy H.P. Acthar® Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.govJul 25, 2017
U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced TherapyJul 18, 2017
Mallinckrodt Commends Governor On Ordering Prescription Drug Monitoring Program In MissouriJul 17, 2017
Mallinckrodt Confirms License Transfer of Synacthen® Depot; Continues Development Efforts for MNK-1411 in Treatment of DMDJul 16, 2017
Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of ScheduleJul 13, 2017
FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular DystrophyJul 12, 2017
Mallinckrodt Finalizes Previously Announced Agreement with DEA and USAOsJul 11, 2017
Mallinckrodt Announces Specialty Brands Investor BriefingJul 05, 2017
Mallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017Jun 29, 2017
MNK H.P. Acthar Gel DN Trial Results AlertJun 26, 2017
Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and OpinionJun 23, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) UpdateJun 22, 2017
Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within HospitalsJun 21, 2017
Mallinckrodt Reinforces Facts in Response to Business Insider “Editorial” Jun 19, 2017
Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS)Jun 14, 2017
MNK Response to Senator McCaskill LetterJun 08, 2017
Mallinckrodt Enrolls First Patient in Phase 3 Trial of StrataGraft® Regenerative Skin TissueJun 07, 2017
Mallinckrodt Updates Facts Refuting Short-Seller ClaimsJun 06, 2017
Mallinckrodt Statement on Sen. Mccaskill Inquiry Related to Ofirmev® (Acetaminophen) InjectionMay 26, 2017
Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis RelapseMay 25, 2017
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis RelapseMay 23, 2017
Mallinckrodt Presents Facts to Refute Short-Seller ClaimsMay 19, 2017
Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal CareMay 19, 2017
Mallinckrodt Opens New Global Centre for Medical Device R&DMay 15, 2017
Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare ConferenceMay 12, 2017
Mallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017May 08, 2017
First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin TissueMay 04, 2017
Mallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis TherapyMay 03, 2017
Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual MeetingApr 28, 2017
Mallinckrodt To Present At UBS Global Healthcare ConferenceApr 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Apr 20, 2017
Mallinckrodt To Present At Deutsche Bank 42nd Annual Healthcare ConferenceApr 05, 2017
Mallinckrodt Statement on DEA and USAOs Agreement in PrincipleApr 03, 2017
Mallinckrodt plc To Report Earnings Results For First Quarter Of Fiscal 2017Mar 24, 2017
Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionMar 20, 2017
Mallinckrodt plc Board Expands Company's Share Repurchase Plan by $1.0 Billion; Company Announces Results of 2017 Annual General MeetingMar 01, 2017
Mallinckrodt To Present At Barclays Global Healthcare ConferenceFeb 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Feb 22, 2017
Updated Mallinckrodt Statement on Extended-Release Methylphenidate TabletsFeb 21, 2017
Mallinckrodt plc Reports Transition Period Results and Announces 2017 GuidanceFeb 07, 2017
Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionJan 30, 2017
Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionJan 27, 2017
Mallinckrodt To Present At Leerink Partners 6th Annual Global Healthcare ConferenceJan 26, 2017
Mallinckrodt And Federal Trade Commission Resolve Questcor MatterJan 18, 2017
Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC InvestigationJan 18, 2017
Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of MallinckrodtJan 04, 2017
Mallinckrodt plc To Report Earnings Results For Transition Period Of Oct. 1, 2016, To Dec. 30, 2016, On Feb. 7, 2017Dec 29, 2016
Mallinckrodt To Present At J.P. Morgan 35th Annual Healthcare ConferenceDec 15, 2016
Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 28th Annual National Forum of the Institute for Healthcare ImprovementDec 07, 2016
Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality IndexDec 05, 2016
Mallinckrodt To Present At BMO Capital Markets 2016 Prescriptions For Success Healthcare ConferenceNov 30, 2016
Mallinckrodt plc Reports Fiscal 2016 Fourth Quarter and Full-Year ResultsNov 29, 2016
Mallinckrodt Updated Statement on Extended-Release Methylphenidate TabletsNov 23, 2016
Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar® Gel in Treatment of Amyotropic Lateral Sclerosis (ALS)Nov 21, 2016
Clinical Pharmacokinetic and Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 15th Annual Pain Medicine Meeting of ASRANov 18, 2016
Study Addresses Possible Impact of H.P. Acthar® Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/PolymyositisNov 17, 2016
Mallinckrodt Statement on Extended-Release Methylphenidate TabletsNov 16, 2016
Clinical Data Analysis on Terlipressin Presented at The Liver Meeting®Nov 16, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for LupusNov 14, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rheumatoid ArthritisNov 14, 2016
Mallinckrodt Announces U.S. FDA Approval of OFIRMEV® IV Bag PresentationNov 08, 2016
Mallinckrodt Statement on U.S. Department of Justice Generics Industry InvestigationNov 07, 2016
Mallinckrodt To Present At 28th Annual Piper Jaffray Healthcare ConferenceNov 02, 2016
Mallinckrodt Builds UK Presence with New Global Corporate Headquarters in Staines-upon-ThamesOct 28, 2016
Mallinckrodt to present at Jefferies 2016 London Healthcare ConferenceOct 26, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in West VirginiaOct 25, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in KentuckyOct 20, 2016
Mallinckrodt plc To Report Fourth Quarter And Full-Year Fiscal 2016 Results Nov. 29, 2016Oct 18, 2016
Children's National Health System Granted $3 Million in Research Funding by Mallinckrodt PharmaceuticalsOct 13, 2016
Validity of Mallinckrodt's INOMAX® Patent Claims UpheldSep 23, 2016
Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 millionSep 19, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsSep 17, 2016
Health Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in TherapySep 01, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsAug 31, 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND ApplicationAug 25, 2016
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionAug 24, 2016
Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home AffairsAug 23, 2016
Mallinckrodt To Present At Morgan Stanley Global Healthcare ConferenceAug 22, 2016
Mallinckrodt To Present At Wells Fargo Securities Healthcare ConferenceAug 19, 2016
Mallinckrodt Continues to Refute Inaccuracies Surrounding its Financial Liabilities Oct 12, 2017
Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017Oct 10, 2017
Mallinckrodt Statement on October 7, 2017, CHEST® Journal ArticleOct 09, 2017
Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic SarcoidosisOct 09, 2017
Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor BriefingOct 04, 2017
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development ProductOct 02, 2017
Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe JaundiceSep 25, 2017
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United StatesSep 22, 2017
Mallinckrodt Announces Election Of David Norton To Its Board Of DirectorsSep 20, 2017
Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other MattersSep 12, 2017
Mallinckrodt Statement on Praxair Patent Infringement RulingSep 05, 2017
Mallinckrodt Statement on Missouri Attorney General InvestigationAug 30, 2017
Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare ConferenceAug 15, 2017
Mallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017Aug 08, 2017
Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid ProductsAug 07, 2017
Mallinckrodt To Present At Wells Fargo Securities 2017 Healthcare ConferenceAug 07, 2017
Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe JaundiceAug 04, 2017
Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid ProductsAug 02, 2017
Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In NeonatesAug 01, 2017
Summary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injection) Published in Advances in TherapyJul 31, 2017
Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring ActivitiesJul 27, 2017
Mallinckrodt Posts Data From Legacy H.P. Acthar® Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.govJul 25, 2017
U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced TherapyJul 18, 2017
Mallinckrodt Commends Governor On Ordering Prescription Drug Monitoring Program In MissouriJul 17, 2017
Mallinckrodt Confirms License Transfer of Synacthen® Depot; Continues Development Efforts for MNK-1411 in Treatment of DMDJul 16, 2017
Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of ScheduleJul 13, 2017
FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular DystrophyJul 12, 2017
Mallinckrodt Finalizes Previously Announced Agreement with DEA and USAOsJul 11, 2017
Mallinckrodt Announces Specialty Brands Investor BriefingJul 05, 2017
Mallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017Jun 29, 2017
MNK H.P. Acthar Gel DN Trial Results AlertJun 26, 2017
Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and OpinionJun 23, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) UpdateJun 22, 2017
Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within HospitalsJun 21, 2017
Mallinckrodt Reinforces Facts in Response to Business Insider “Editorial” Jun 19, 2017
Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS)Jun 14, 2017
MNK Response to Senator McCaskill LetterJun 08, 2017
Mallinckrodt Enrolls First Patient in Phase 3 Trial of StrataGraft® Regenerative Skin TissueJun 07, 2017
Mallinckrodt Updates Facts Refuting Short-Seller ClaimsJun 06, 2017
Mallinckrodt Statement on Sen. Mccaskill Inquiry Related to Ofirmev® (Acetaminophen) InjectionMay 26, 2017
Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis RelapseMay 25, 2017
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis RelapseMay 23, 2017
Mallinckrodt Presents Facts to Refute Short-Seller ClaimsMay 19, 2017
Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal CareMay 19, 2017
Mallinckrodt Opens New Global Centre for Medical Device R&DMay 15, 2017
Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare ConferenceMay 12, 2017
Mallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017May 08, 2017
First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin TissueMay 04, 2017
Mallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis TherapyMay 03, 2017
Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual MeetingApr 28, 2017
Mallinckrodt To Present At UBS Global Healthcare ConferenceApr 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Apr 20, 2017
Mallinckrodt To Present At Deutsche Bank 42nd Annual Healthcare ConferenceApr 05, 2017
Mallinckrodt Statement on DEA and USAOs Agreement in PrincipleApr 03, 2017
Mallinckrodt plc To Report Earnings Results For First Quarter Of Fiscal 2017Mar 24, 2017
Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionMar 20, 2017
Mallinckrodt plc Board Expands Company's Share Repurchase Plan by $1.0 Billion; Company Announces Results of 2017 Annual General MeetingMar 01, 2017
Mallinckrodt To Present At Barclays Global Healthcare ConferenceFeb 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Feb 22, 2017
Updated Mallinckrodt Statement on Extended-Release Methylphenidate TabletsFeb 21, 2017
Mallinckrodt plc Reports Transition Period Results and Announces 2017 GuidanceFeb 07, 2017
Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionJan 30, 2017
Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionJan 27, 2017
Mallinckrodt To Present At Leerink Partners 6th Annual Global Healthcare ConferenceJan 26, 2017
Mallinckrodt And Federal Trade Commission Resolve Questcor MatterJan 18, 2017
Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC InvestigationJan 18, 2017
Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of MallinckrodtJan 04, 2017
Mallinckrodt plc To Report Earnings Results For Transition Period Of Oct. 1, 2016, To Dec. 30, 2016, On Feb. 7, 2017Dec 29, 2016
Mallinckrodt To Present At J.P. Morgan 35th Annual Healthcare ConferenceDec 15, 2016
Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 28th Annual National Forum of the Institute for Healthcare ImprovementDec 07, 2016
Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality IndexDec 05, 2016
Mallinckrodt To Present At BMO Capital Markets 2016 Prescriptions For Success Healthcare ConferenceNov 30, 2016
Mallinckrodt plc Reports Fiscal 2016 Fourth Quarter and Full-Year ResultsNov 29, 2016
Mallinckrodt Updated Statement on Extended-Release Methylphenidate TabletsNov 23, 2016
Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar® Gel in Treatment of Amyotropic Lateral Sclerosis (ALS)Nov 21, 2016
Clinical Pharmacokinetic and Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 15th Annual Pain Medicine Meeting of ASRANov 18, 2016
Study Addresses Possible Impact of H.P. Acthar® Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/PolymyositisNov 17, 2016
Mallinckrodt Statement on Extended-Release Methylphenidate TabletsNov 16, 2016
Clinical Data Analysis on Terlipressin Presented at The Liver Meeting®Nov 16, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for LupusNov 14, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rheumatoid ArthritisNov 14, 2016
Mallinckrodt Announces U.S. FDA Approval of OFIRMEV® IV Bag PresentationNov 08, 2016
Mallinckrodt Statement on U.S. Department of Justice Generics Industry InvestigationNov 07, 2016
Mallinckrodt To Present At 28th Annual Piper Jaffray Healthcare ConferenceNov 02, 2016
Mallinckrodt Builds UK Presence with New Global Corporate Headquarters in Staines-upon-ThamesOct 28, 2016
Mallinckrodt to present at Jefferies 2016 London Healthcare ConferenceOct 26, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in West VirginiaOct 25, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in KentuckyOct 20, 2016
Mallinckrodt plc To Report Fourth Quarter And Full-Year Fiscal 2016 Results Nov. 29, 2016Oct 18, 2016
Children's National Health System Granted $3 Million in Research Funding by Mallinckrodt PharmaceuticalsOct 13, 2016
Validity of Mallinckrodt's INOMAX® Patent Claims UpheldSep 23, 2016
Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 millionSep 19, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsSep 17, 2016
Health Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in TherapySep 01, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsAug 31, 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND ApplicationAug 25, 2016
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionAug 24, 2016
Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home AffairsAug 23, 2016
Mallinckrodt To Present At Morgan Stanley Global Healthcare ConferenceAug 22, 2016
Mallinckrodt To Present At Wells Fargo Securities Healthcare ConferenceAug 19, 2016
Mallinckrodt Continues to Refute Inaccuracies Surrounding its Financial Liabilities Oct 12, 2017
Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017Oct 10, 2017
Mallinckrodt Statement on October 7, 2017, CHEST® Journal ArticleOct 09, 2017
Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic SarcoidosisOct 09, 2017
Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor BriefingOct 04, 2017
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development ProductOct 02, 2017
Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe JaundiceSep 25, 2017
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United StatesSep 22, 2017
Mallinckrodt Announces Election Of David Norton To Its Board Of DirectorsSep 20, 2017
Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other MattersSep 12, 2017
Mallinckrodt Statement on Praxair Patent Infringement RulingSep 05, 2017
Mallinckrodt Statement on Missouri Attorney General InvestigationAug 30, 2017
Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare ConferenceAug 15, 2017
Mallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017Aug 08, 2017
Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid ProductsAug 07, 2017
Mallinckrodt To Present At Wells Fargo Securities 2017 Healthcare ConferenceAug 07, 2017
Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe JaundiceAug 04, 2017
Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid ProductsAug 02, 2017
Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In NeonatesAug 01, 2017
Summary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injection) Published in Advances in TherapyJul 31, 2017
Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring ActivitiesJul 27, 2017
Mallinckrodt Posts Data From Legacy H.P. Acthar® Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.govJul 25, 2017
U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced TherapyJul 18, 2017
Mallinckrodt Commends Governor On Ordering Prescription Drug Monitoring Program In MissouriJul 17, 2017
Mallinckrodt Confirms License Transfer of Synacthen® Depot; Continues Development Efforts for MNK-1411 in Treatment of DMDJul 16, 2017
Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of ScheduleJul 13, 2017
FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular DystrophyJul 12, 2017
Mallinckrodt Finalizes Previously Announced Agreement with DEA and USAOsJul 11, 2017
Mallinckrodt Announces Specialty Brands Investor BriefingJul 05, 2017
Mallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017Jun 29, 2017
MNK H.P. Acthar Gel DN Trial Results AlertJun 26, 2017
Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and OpinionJun 23, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) UpdateJun 22, 2017
Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within HospitalsJun 21, 2017
Mallinckrodt Reinforces Facts in Response to Business Insider “Editorial” Jun 19, 2017
Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS)Jun 14, 2017
MNK Response to Senator McCaskill LetterJun 08, 2017
Mallinckrodt Enrolls First Patient in Phase 3 Trial of StrataGraft® Regenerative Skin TissueJun 07, 2017
Mallinckrodt Updates Facts Refuting Short-Seller ClaimsJun 06, 2017
Mallinckrodt Statement on Sen. Mccaskill Inquiry Related to Ofirmev® (Acetaminophen) InjectionMay 26, 2017
Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis RelapseMay 25, 2017
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis RelapseMay 23, 2017
Mallinckrodt Presents Facts to Refute Short-Seller ClaimsMay 19, 2017
Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal CareMay 19, 2017
Mallinckrodt Opens New Global Centre for Medical Device R&DMay 15, 2017
Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare ConferenceMay 12, 2017
Mallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017May 08, 2017
First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin TissueMay 04, 2017
Mallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis TherapyMay 03, 2017
Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual MeetingApr 28, 2017
Mallinckrodt To Present At UBS Global Healthcare ConferenceApr 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Apr 20, 2017
Mallinckrodt To Present At Deutsche Bank 42nd Annual Healthcare ConferenceApr 05, 2017
Mallinckrodt Statement on DEA and USAOs Agreement in PrincipleApr 03, 2017
Mallinckrodt plc To Report Earnings Results For First Quarter Of Fiscal 2017Mar 24, 2017
Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionMar 20, 2017
Mallinckrodt plc Board Expands Company's Share Repurchase Plan by $1.0 Billion; Company Announces Results of 2017 Annual General MeetingMar 01, 2017
Mallinckrodt To Present At Barclays Global Healthcare ConferenceFeb 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Feb 22, 2017
Updated Mallinckrodt Statement on Extended-Release Methylphenidate TabletsFeb 21, 2017
Mallinckrodt plc Reports Transition Period Results and Announces 2017 GuidanceFeb 07, 2017
Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionJan 30, 2017
Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionJan 27, 2017
Mallinckrodt To Present At Leerink Partners 6th Annual Global Healthcare ConferenceJan 26, 2017
Mallinckrodt And Federal Trade Commission Resolve Questcor MatterJan 18, 2017
Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC InvestigationJan 18, 2017
Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of MallinckrodtJan 04, 2017
Mallinckrodt plc To Report Earnings Results For Transition Period Of Oct. 1, 2016, To Dec. 30, 2016, On Feb. 7, 2017Dec 29, 2016
Mallinckrodt To Present At J.P. Morgan 35th Annual Healthcare ConferenceDec 15, 2016
Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 28th Annual National Forum of the Institute for Healthcare ImprovementDec 07, 2016
Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality IndexDec 05, 2016
Mallinckrodt To Present At BMO Capital Markets 2016 Prescriptions For Success Healthcare ConferenceNov 30, 2016
Mallinckrodt plc Reports Fiscal 2016 Fourth Quarter and Full-Year ResultsNov 29, 2016
Mallinckrodt Updated Statement on Extended-Release Methylphenidate TabletsNov 23, 2016
Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar® Gel in Treatment of Amyotropic Lateral Sclerosis (ALS)Nov 21, 2016
Clinical Pharmacokinetic and Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 15th Annual Pain Medicine Meeting of ASRANov 18, 2016
Study Addresses Possible Impact of H.P. Acthar® Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/PolymyositisNov 17, 2016
Mallinckrodt Statement on Extended-Release Methylphenidate TabletsNov 16, 2016
Clinical Data Analysis on Terlipressin Presented at The Liver Meeting®Nov 16, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for LupusNov 14, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rheumatoid ArthritisNov 14, 2016
Mallinckrodt Announces U.S. FDA Approval of OFIRMEV® IV Bag PresentationNov 08, 2016
Mallinckrodt Statement on U.S. Department of Justice Generics Industry InvestigationNov 07, 2016
Mallinckrodt To Present At 28th Annual Piper Jaffray Healthcare ConferenceNov 02, 2016
Mallinckrodt Builds UK Presence with New Global Corporate Headquarters in Staines-upon-ThamesOct 28, 2016
Mallinckrodt to present at Jefferies 2016 London Healthcare ConferenceOct 26, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in West VirginiaOct 25, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in KentuckyOct 20, 2016
Mallinckrodt plc To Report Fourth Quarter And Full-Year Fiscal 2016 Results Nov. 29, 2016Oct 18, 2016
Children's National Health System Granted $3 Million in Research Funding by Mallinckrodt PharmaceuticalsOct 13, 2016
Validity of Mallinckrodt's INOMAX® Patent Claims UpheldSep 23, 2016
Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 millionSep 19, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsSep 17, 2016
Health Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in TherapySep 01, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsAug 31, 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND ApplicationAug 25, 2016
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionAug 24, 2016
Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home AffairsAug 23, 2016
Mallinckrodt To Present At Morgan Stanley Global Healthcare ConferenceAug 22, 2016
Mallinckrodt To Present At Wells Fargo Securities Healthcare ConferenceAug 19, 2016
Mallinckrodt Continues to Refute Inaccuracies Surrounding its Financial Liabilities Oct 12, 2017
Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017Oct 10, 2017
Mallinckrodt Statement on October 7, 2017, CHEST® Journal ArticleOct 09, 2017
Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic SarcoidosisOct 09, 2017
Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor BriefingOct 04, 2017
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development ProductOct 02, 2017
Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe JaundiceSep 25, 2017
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United StatesSep 22, 2017
Mallinckrodt Announces Election Of David Norton To Its Board Of DirectorsSep 20, 2017
Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other MattersSep 12, 2017
Mallinckrodt Statement on Praxair Patent Infringement RulingSep 05, 2017
Mallinckrodt Statement on Missouri Attorney General InvestigationAug 30, 2017
Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare ConferenceAug 15, 2017
Mallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017Aug 08, 2017
Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid ProductsAug 07, 2017
Mallinckrodt To Present At Wells Fargo Securities 2017 Healthcare ConferenceAug 07, 2017
Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe JaundiceAug 04, 2017
Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid ProductsAug 02, 2017
Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In NeonatesAug 01, 2017
Summary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injection) Published in Advances in TherapyJul 31, 2017
Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring ActivitiesJul 27, 2017
Mallinckrodt Posts Data From Legacy H.P. Acthar® Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.govJul 25, 2017
U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced TherapyJul 18, 2017
Mallinckrodt Commends Governor On Ordering Prescription Drug Monitoring Program In MissouriJul 17, 2017
Mallinckrodt Confirms License Transfer of Synacthen® Depot; Continues Development Efforts for MNK-1411 in Treatment of DMDJul 16, 2017
Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of ScheduleJul 13, 2017
FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular DystrophyJul 12, 2017
Mallinckrodt Finalizes Previously Announced Agreement with DEA and USAOsJul 11, 2017
Mallinckrodt Announces Specialty Brands Investor BriefingJul 05, 2017
Mallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017Jun 29, 2017
MNK H.P. Acthar Gel DN Trial Results AlertJun 26, 2017
Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and OpinionJun 23, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection) UpdateJun 22, 2017
Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within HospitalsJun 21, 2017
Mallinckrodt Reinforces Facts in Response to Business Insider “Editorial” Jun 19, 2017
Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS)Jun 14, 2017
MNK Response to Senator McCaskill LetterJun 08, 2017
Mallinckrodt Enrolls First Patient in Phase 3 Trial of StrataGraft® Regenerative Skin TissueJun 07, 2017
Mallinckrodt Updates Facts Refuting Short-Seller ClaimsJun 06, 2017
Mallinckrodt Statement on Sen. Mccaskill Inquiry Related to Ofirmev® (Acetaminophen) InjectionMay 26, 2017
Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis RelapseMay 25, 2017
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis RelapseMay 23, 2017
Mallinckrodt Presents Facts to Refute Short-Seller ClaimsMay 19, 2017
Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal CareMay 19, 2017
Mallinckrodt Opens New Global Centre for Medical Device R&DMay 15, 2017
Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare ConferenceMay 12, 2017
Mallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017May 08, 2017
First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin TissueMay 04, 2017
Mallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis TherapyMay 03, 2017
Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual MeetingApr 28, 2017
Mallinckrodt To Present At UBS Global Healthcare ConferenceApr 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Apr 20, 2017
Mallinckrodt To Present At Deutsche Bank 42nd Annual Healthcare ConferenceApr 05, 2017
Mallinckrodt Statement on DEA and USAOs Agreement in PrincipleApr 03, 2017
Mallinckrodt plc To Report Earnings Results For First Quarter Of Fiscal 2017Mar 24, 2017
Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionMar 20, 2017
Mallinckrodt plc Board Expands Company's Share Repurchase Plan by $1.0 Billion; Company Announces Results of 2017 Annual General MeetingMar 01, 2017
Mallinckrodt To Present At Barclays Global Healthcare ConferenceFeb 24, 2017
Mallinckrodt Statement on H.P. Acthar® Gel (Repository Corticotropin Injection)Feb 22, 2017
Updated Mallinckrodt Statement on Extended-Release Methylphenidate TabletsFeb 21, 2017
Mallinckrodt plc Reports Transition Period Results and Announces 2017 GuidanceFeb 07, 2017
Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 MillionJan 30, 2017
Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionJan 27, 2017
Mallinckrodt To Present At Leerink Partners 6th Annual Global Healthcare ConferenceJan 26, 2017
Mallinckrodt And Federal Trade Commission Resolve Questcor MatterJan 18, 2017
Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC InvestigationJan 18, 2017
Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of MallinckrodtJan 04, 2017
Mallinckrodt plc To Report Earnings Results For Transition Period Of Oct. 1, 2016, To Dec. 30, 2016, On Feb. 7, 2017Dec 29, 2016
Mallinckrodt To Present At J.P. Morgan 35th Annual Healthcare ConferenceDec 15, 2016
Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 28th Annual National Forum of the Institute for Healthcare ImprovementDec 07, 2016
Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality IndexDec 05, 2016
Mallinckrodt To Present At BMO Capital Markets 2016 Prescriptions For Success Healthcare ConferenceNov 30, 2016
Mallinckrodt plc Reports Fiscal 2016 Fourth Quarter and Full-Year ResultsNov 29, 2016
Mallinckrodt Updated Statement on Extended-Release Methylphenidate TabletsNov 23, 2016
Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar® Gel in Treatment of Amyotropic Lateral Sclerosis (ALS)Nov 21, 2016
Clinical Pharmacokinetic and Health Economic Data on OFIRMEV® (Acetaminophen) Injection Presented at 15th Annual Pain Medicine Meeting of ASRANov 18, 2016
Study Addresses Possible Impact of H.P. Acthar® Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/PolymyositisNov 17, 2016
Mallinckrodt Statement on Extended-Release Methylphenidate TabletsNov 16, 2016
Clinical Data Analysis on Terlipressin Presented at The Liver Meeting®Nov 16, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for LupusNov 14, 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rheumatoid ArthritisNov 14, 2016
Mallinckrodt Announces U.S. FDA Approval of OFIRMEV® IV Bag PresentationNov 08, 2016
Mallinckrodt Statement on U.S. Department of Justice Generics Industry InvestigationNov 07, 2016
Mallinckrodt To Present At 28th Annual Piper Jaffray Healthcare ConferenceNov 02, 2016
Mallinckrodt Builds UK Presence with New Global Corporate Headquarters in Staines-upon-ThamesOct 28, 2016
Mallinckrodt to present at Jefferies 2016 London Healthcare ConferenceOct 26, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in West VirginiaOct 25, 2016
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in KentuckyOct 20, 2016
Mallinckrodt plc To Report Fourth Quarter And Full-Year Fiscal 2016 Results Nov. 29, 2016Oct 18, 2016
Children's National Health System Granted $3 Million in Research Funding by Mallinckrodt PharmaceuticalsOct 13, 2016
Validity of Mallinckrodt's INOMAX® Patent Claims UpheldSep 23, 2016
Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 millionSep 19, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsSep 17, 2016
Health Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in TherapySep 01, 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute ProductsAug 31, 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND ApplicationAug 25, 2016
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 MillionAug 24, 2016
Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home AffairsAug 23, 2016
Mallinckrodt To Present At Morgan Stanley Global Healthcare ConferenceAug 22, 2016
Mallinckrodt To Present At Wells Fargo Securities Healthcare ConferenceAug 19, 2016

310比分网

310比分网

310比分网

310比分网

Our Culture310比分网

Our Culture
310比分网